SLDB$5.66
Chart
Performance
Key Stats
AI SLDB Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuySolid Biosciences Inc. (SLDB) shows strong potential driven by its innovative therapies and a positive trajectory in clinical trials, supported by a robust scientific foundation. While currently loss-making, its strategic partnerships and focused pipeline suggest significant future growth. Technical indicators are largely positive, indicating a bullish trend, but near-term overbought conditions warrant attention.
Thematic
Solid Biosciences is well-positioned within the rapidly growing biotechnology and gene therapy sectors, addressing critical unmet needs in rare genetic diseases.
Fundamental
The company is in the development stage, exhibiting negative earnings and revenue, which is typical for its industry. Its financial health is characterized by a strong cash position relative to its debt, but it relies heavily on financing activities to fund its operations.
Technical
SLDB exhibits strong positive momentum across multiple timeframes, with prices consistently trading above key moving averages. While indicators suggest potential for a short-term pullback due to overbought conditions, the overall trend remains strongly bullish.
| Factor | Score |
|---|---|
| Gene Therapy & Rare Diseases | 95 |
| Biotechnology Innovation | 90 |
| Clinical Trial Progress | 80 |
| Strategic Partnerships | 85 |
| Regulatory Landscape (Biotech) | 70 |
| Factor | Score |
|---|---|
| Valuation | 20 |
| Profitability | 10 |
| Growth | 0 |
| Balance Sheet Health | 80 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 90 |
| Momentum | 55 |
| Volume Confirmation | 70 |
| Support & Resistance | 80 |
| Performance Metrics | 90 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Significant Short-Term Momentum
The stock price has seen a positive change of +4.79% (+$0.32) in the latest trading session, closing at $7.0. Performance over the last 5 days was +12.36%, indicating strong recent upward momentum.
Targeted Therapeutic Development
Solid Biosciences Inc. is focused on developing therapies for specific neuromuscular and cardiac diseases, with lead candidates in clinical trials for Duchenne muscular dystrophy and Friedreich's ataxia. This specialization suggests a clear strategic direction.
Bearish Points (8)
Persistent Net Losses
The company has consistently reported negative Earnings Per Share (EPS) on a trailing twelve months (TTM) basis (-$3.01) and in recent quarterly reports (e.g., -0.59 in Q2 2025), indicating a lack of profitability.
Negative P/E Ratio
The Price-to-Earnings (P/E) ratio is null or negative across all reported periods (e.g., -4.7 TTM, -2.5 for 2024), which is typical for pre-revenue or pre-profitability biotech companies, but indicates no current earnings support for the stock price.
Calendar
August 2025
12
Next Earnings Date
H: $-0.42
A: $-0.49
L: $-0.59
Profile
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Seasonals
Price Target
15.91 USD
The 39 analysts offering 1 year price forecasts for SLDB have a max estimate of 20.00 and a min estimate of 10.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Primary direct competitor in Duchenne Muscular Dystrophy (DMD) gene therapy with approved therapies and advanced pipeline, targeting similar patient populations.
Weight: 95
Major pharmaceutical company with a late-stage gene therapy candidate for DMD, a direct and significant competitor in the same therapeutic area.
Weight: 92
Company with approved DMD treatments and an active gene therapy pipeline, making it a key player in the overall DMD therapeutic landscape.
Weight: 90
Leading biotechnology company with a strong focus on neurological diseases and a growing gene therapy pipeline, potentially intersecting with SLDB's focus.